L’Oréal Influences Sanofi CEO Ouster and Successor Appointment

THE WHAT? L’Oréal performed a pivotal position within the removing of Sanofi CEO Paul Hudson and the appointment of Merck KGaA CEO Belén Garijo as his successor in a major management shake-up on the French pharmaceutical group.

THE DETAILS As Sanofi’s largest shareholder, holding 7.2% of the capital and 13.1% of voting rights, L’Oréal pushed for change amid rising investor dissatisfaction over R&D setbacks and weak share worth efficiency underneath Hudson’s six-and-a-half-year tenure. Hudson, who was due for mandate renewal at Sanofi’s April 29 AGM, was changed following board discussions that had reportedly been underway for 2 years.

Garijo, a former Sanofi government and L’Oréal board member from 2014 to 2024, was chosen after a multi-year succession course of. Her nomination would require shareholder approval to raise Sanofi’s 65-year CEO age cap. Whereas some traders questioned her observe report at Merck, Sanofi’s board said that succession planning was carried out in keeping with governance guidelines. Hudson’s tenure had included elevated R&D funding—rising to €6.5 billion in 2023 and up 20% two years later—however didn’t ship a transparent successor to blockbuster drug Dupixent, contributing to mounting stress.

THE WHY? The management change displays shareholder considerations over pipeline efficiency, long-term development technique and governance alignment, with L’Oréal leveraging its board affect to assist steer Sanofi towards a brand new strategic section.

Supply: Bloomberg